The US Food and Drug Administration (FDA) has approved raltegravir tablets (Isentress) for treating HIV-1 infection, in combination with other antiretroviral medicines.
Raltegravir is the first of a new class of medicines, HIV integrase inhibitors, which block an enzyme the virus needs to multiply. Used with other medicines, it can lower the amount of HIV in the blood and raise the number of CD4+ T cells.
The most common side effects are diarrhoea, nausea and headache. Blood tests also showed abnormal rises in muscle enzymes, so care is needed in patients with muscle problems.
0
Like
0
Love
0
Angry
0
Dislike
0
